KCM Investment Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.38M Buy
22,809
+1,938
+9% +$113K 0.05% 192
2025
Q4
$1.13M Buy
20,871
+174
+0.8% +$8.37K 0.04% 208
2025
Q3
$933K Sell
20,697
-186
-0.9% -$8.69K 0.03% 217
2025
Q2
$967K Sell
20,883
-269
-1% -$13.2K 0.03% 215
2025
Q1
$1.29M Sell
21,152
-324
-2% -$18.9K 0.05% 185
2024
Q4
$1.21M Sell
21,476
-622
-3% -$34.8K 0.04% 190
2024
Q3
$1.14M Sell
22,098
-880
-4% -$41.3K 0.04% 200
2024
Q2
$954K Sell
22,978
-2,375
-9% -$106K 0.03% 215
2024
Q1
$1.37M Sell
25,353
-26,681
-51% -$1.36M 0.05% 191
2023
Q4
$2.67M Sell
52,034
-13,784
-21% -$724K 0.11% 131
2023
Q3
$3.82M Sell
65,818
-2,700
-4% -$165K 0.16% 106
2023
Q2
$4.38M Sell
68,518
-20,656
-23% -$1.39M 0.18% 105
2023
Q1
$6.18M Buy
89,174
+8,421
+10% +$594K 0.25% 91
2022
Q4
$5.81M Sell
80,753
-2,300
-3% -$173K 0.25% 90
2022
Q3
$5.9M Sell
83,053
-171
-0.2% -$12.4K 0.27% 85
2022
Q2
$6.41M Sell
83,224
-4,401
-5% -$335K 0.28% 83
2022
Q1
$6.4M Sell
87,625
-2,958
-3% -$199K 0.23% 94
2021
Q4
$5.65M Sell
90,583
-4,682
-5% -$275K 0.2% 102
2021
Q3
$5.64M Sell
95,265
-925
-1% -$60.9K 0.22% 94
2021
Q2
$6.43M Sell
96,190
-9,509
-9% -$620K 0.26% 85
2021
Q1
$6.67M Sell
105,699
-2,986
-3% -$186K 0.3% 80
2020
Q4
$6.74M Sell
108,685
-4,243
-4% -$261K 0.33% 73
2020
Q3
$6.81M Sell
112,928
-12,867
-10% -$774K 0.38% 60
2020
Q2
$7.4M Buy
125,795
+7,585
+6% +$454K 0.42% 59
2020
Q1
$6.59M Sell
118,210
-6,595
-5% -$403K 0.44% 62
2019
Q4
$8.01M Sell
124,805
-9,176
-7% -$526K 0.44% 64
2019
Q3
$6.79M Sell
133,981
-22,201
-14% -$1.04M 0.39% 72
2019
Q2
$7.08M Sell
156,182
-11,862
-7% -$553K 0.42% 70
2019
Q1
$8.02M Sell
168,044
-9,548
-5% -$476K 0.52% 58
2018
Q4
$9.23M Sell
177,592
-6,213
-3% -$334K 0.61% 46
2018
Q3
$11.4M Sell
183,805
-8,163
-4% -$484K 0.65% 43
2018
Q2
$10.6M Sell
191,968
-84,456
-31% -$4.56M 0.65% 40
2018
Q1
$17.5M Sell
276,424
-6,121
-2% -$394K 1.06% 23
2017
Q4
$17.3M Sell
282,545
-9,890
-3% -$619K 1.01% 24
2017
Q3
$18.6M Sell
292,435
-2,655
-0.9% -$155K 1.14% 14
2017
Q2
$16.4M Sell
295,090
-2,576
-0.9% -$140K 1.03% 20
2017
Q1
$16.2M Buy
297,666
+2,270
+0.8% +$125K 1.03% 17
2016
Q4
$17.3M Sell
295,396
-4,320
-1% -$236K 1.16% 14
2016
Q3
$16.2M Buy
299,716
+9,715
+3% +$624K 1.11% 13
2016
Q2
$21.3M Buy
290,001
+250
+0.1% +$17.7K 1.49% 9
2016
Q1
$18.5M Buy
289,751
+8,280
+3% +$522K 1.36% 9
2015
Q4
$19.4M Buy
281,471
+3,147
+1% +$208K 1.53% 8
2015
Q3
$16.5M Buy
278,324
+8,442
+3% +$536K 1.37% 8
2015
Q2
$18M Buy
269,882
+3,892
+1% +$256K 1.43% 8
2015
Q1
$17.2M Buy
265,990
+441
+0.2% +$27.6K 1.37% 8
2014
Q4
$15.7M Buy
265,549
+10,787
+4% +$608K 1.32% 8
2014
Q3
$13M Buy
254,762
+5,410
+2% +$270K 1.19% 12
2014
Q2
$12.1M Buy
249,352
+14,891
+6% +$734K 1.13% 11
2014
Q1
$12.2M Buy
234,461
+3,746
+2% +$199K 1.26% 11
2013
Q4
$12.3M Buy
230,715
+6,261
+3% +$319K 1.33% 11
2013
Q3
$10.4M Sell
224,454
-10,463
-4% -$459K 1.24% 12
2013
Q2
$10.5M Buy
+234,917
New +$10.2M 1.27% 11

Other funds holding BMY

KCM Investment Advisors's BMY Position: Q1 2026 in Review

KCM Investment Advisors increased its Bristol-Myers Squibb (BMY) stake by 9.3% in Q1 2026, buying an estimated $113K and bringing the position to 22,809 shares worth $1.38M. The position accounts for 0.05% of the portfolio, ranked #192.

KCM Investment Advisors first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $21.3M in Q2 2016. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • KCM Investment Advisors held 22,809 shares of Bristol-Myers Squibb worth $1.38M as of Q1 2026.
  • KCM Investment Advisors bought 1,938 Bristol-Myers Squibb shares in Q1 2026, an estimated $113K.
  • Bristol-Myers Squibb made up 0.05% of KCM Investment Advisors's portfolio in Q1 2026, its #192 holding.
  • KCM Investment Advisors first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • KCM Investment Advisors's Bristol-Myers Squibb position peaked at $21.3M in Q2 2016.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on KCM Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.